This paper is in the following e-collection/theme issue:

Non-Randomized Study Protocols and Methods (Non-eHealth) (571) Cancer Survivorship (258) Children and Young People With Cancer, Pediatric Oncology (59) Precision Medicine and Genetics (48) Cardiology (159)

Published on in Vol 11, No 2 (2022): February

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/27898, first published .
Cardiovascular Health Status And Genetic Risk In Survivors of Childhood Neuroblastoma and Nephroblastoma Treated With Doxorubicin: Protocol of the Pharmacogenetic Part of the LESS-Anthra Cross-Sectional Cohort Study

Cardiovascular Health Status And Genetic Risk In Survivors of Childhood Neuroblastoma and Nephroblastoma Treated With Doxorubicin: Protocol of the Pharmacogenetic Part of the LESS-Anthra Cross-Sectional Cohort Study

Cardiovascular Health Status And Genetic Risk In Survivors of Childhood Neuroblastoma and Nephroblastoma Treated With Doxorubicin: Protocol of the Pharmacogenetic Part of the LESS-Anthra Cross-Sectional Cohort Study

Authors of this article:

Oliver Zolk1 Author Orcid Image ;   Annika von dem Knesebeck2 Author Orcid Image ;   Norbert Graf3 Author Orcid Image ;   Thorsten Simon4 Author Orcid Image ;   Barbara Hero4 Author Orcid Image ;   Hashim Abdul-Khaliq5 Author Orcid Image ;   Mohamed Abd El Rahman5 Author Orcid Image ;   Claudia Spix6 Author Orcid Image ;   Benjamin Mayer7 Author Orcid Image ;   Susanne Elsner8 Author Orcid Image ;   Judith Gebauer9 Author Orcid Image ;   Thorsten Langer10 Author Orcid Image
Article Authors Cited by (4) Tweetations (2) Metrics

Journals

  1. Nyangwara V, Mazhindu T, Chikwambi Z, Masimirembwa C, Campbell T, Borok M, Ndlovu N. Cardiotoxicity and pharmacogenetics of doxorubicin in black Zimbabwean breast cancer patients. British Journal of Clinical Pharmacology 2024;90(8):1782 View
  2. Gündüz A, Duman D, Başbinar Y, Taşdelen B, Küpeli S, Karpuz D. The Role of RARG rs2229774, SLC28A3 rs7853758, and UGT1A6*4 rs17863783 Single-nucleotide Polymorphisms in the Doxorubicin-induced Cardiotoxicity in Solid Childhood Tumors. Journal of Pediatric Hematology/Oncology 2024;46(1):e65 View
  3. Aleshchenko E, Apfelbacher C, Baust K, Calaminus G, Droege P, Glogner J, Horenkamp-Sonntag D, Ihle P, Kaatsch P, Klein M, Kloppe T, Kuepper-Nybelen J, Langer T, Luepkes C, Marschall U, Meier I, Merzenich H, Spix C, Swart E, Trocchi P. VersKiK: Study protocol of an observational registry-based study on the current state of follow-up care and adherence to follow-up guidelines after cancer in childhood or adolescence. Cancer Epidemiology 2023;87:102469 View
  4. Liu Y, Zhang D, Kong M, Wang Y, Mei H, Shan C, Meng J, Zou Y, Wang J. Synaptic vesicle protein 2-targeted doxorubicin-loaded liposome for effective neuroblastoma therapy. Biomedicine & Pharmacotherapy 2024;180:117548 View